Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey

Yildiz I., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., ...More

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.12, pp.1380-1387, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 12
  • Publication Date: 2011
  • Doi Number: 10.1093/jjco/hyr151
  • Journal Name: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1380-1387
  • Istanbul University Affiliated: Yes

Abstract

Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.